IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs), primarily anti-PD-1, are currently used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, only a minority of patients benefit from these costly therapies. Therefore, there is an unmet need to better...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieviläinen, Meri, Saavalainen, Jordan, Adnan-Awad, Shady, Salo, Tuula, Al-Samadi, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963946/
https://www.ncbi.nlm.nih.gov/pubmed/35359980
http://dx.doi.org/10.3389/fimmu.2022.812822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963946/
https://www.ncbi.nlm.nih.gov/pubmed/35359980
http://dx.doi.org/10.3389/fimmu.2022.812822

Ejemplares similares